Literature DB >> 18726613

The physiological effects of IGF-1 (class 1:Ea transgene) over-expression on exercise-induced damage and adaptation in dystrophic muscles of mdx mice.

James A Ridgley1, Gavin J Pinniger, Peter W Hamer, Miranda D Grounds.   

Abstract

Duchenne muscular dystrophy (DMD) is a genetic disorder in which muscle weakness and fragility contribute to ongoing muscle degeneration. Although exercise-induced muscle damage is associated with adaptation that protects normal muscle from further damage, exploiting this process to protect dystrophic muscle has been avoided for fear of inducing excessive muscle degeneration. However, muscle-specific over-expression of the class 1:Ea isoform of insulin-like growth factor-1 (IGF-1) reduces myofibre necrosis in dystrophic mdx mice (a model for DMD) and, therefore, may enhance the adaptation process in response to eccentric exercise. To test this hypothesis, we evaluated the effect of transgenic class 1:Ea IGF-1 over-expression on the susceptibility to muscle damage and subsequent adaptation in 12-week-old dystrophic mdx and non-dystrophic control mice. Experiments were conducted in vivo using a custom-built isokinetic mouse dynamometer to measure the deficit in joint torque (indicating muscle damage) after 20 maximal lengthening (eccentric) contractions. Adaptation to this damaging exercise was evaluated by repeating the protocol 7 days after the initial exercise. The over-expression of IGF-1 significantly increased the normalised joint torque in non-dystrophic mice and appeared to ameliorate the muscle weakness in dystrophic mice. All mice displayed a marked reduction in the susceptibility to muscle damage on day 7; however, this adaptation was unaffected by IGF-1, showing that IGF-1 does not protect the dystrophic muscles of adult mdx mice against damage resulting from maximal lengthening contractions.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18726613     DOI: 10.1007/s00424-008-0568-4

Source DB:  PubMed          Journal:  Pflugers Arch        ISSN: 0031-6768            Impact factor:   3.657


  46 in total

1.  An apparatus to measure in vivo biomechanical behavior of dorsi- and plantarflexors of mouse ankle.

Authors:  J A Ashton-Miller; Y He; V A Kadhiresan; D A McCubbrey; J A Faulkner
Journal:  J Appl Physiol (1985)       Date:  1992-03

2.  Response to high-intensity eccentric muscle contractions in persons with myopathic disease.

Authors:  D D Kilmer; S G Aitkens; N C Wright; M A McCrory
Journal:  Muscle Nerve       Date:  2001-09       Impact factor: 3.217

3.  Effects of prior concentric training on eccentric exercise induced muscle damage.

Authors:  N Gleeson; R Eston; V Marginson; M McHugh
Journal:  Br J Sports Med       Date:  2003-04       Impact factor: 13.800

4.  Evans Blue Dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability.

Authors:  P W Hamer; J M McGeachie; M J Davies; M D Grounds
Journal:  J Anat       Date:  2002-01       Impact factor: 2.610

5.  Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment.

Authors:  Hannah G Radley; Marilyn J Davies; Miranda D Grounds
Journal:  Neuromuscul Disord       Date:  2008-01-22       Impact factor: 4.296

6.  Endurance capacity in maturing mdx mice is markedly enhanced by combined voluntary wheel running and green tea extract.

Authors:  Jarrod A Call; Kevin A Voelker; Andrew V Wolff; Ryan P McMillan; Nick P Evans; Matthew W Hulver; Robert J Talmadge; Robert W Grange
Journal:  J Appl Physiol (1985)       Date:  2008-06-26

7.  Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.

Authors:  Annamaria De Luca; Sabata Pierno; Antonella Liantonio; Michela Cetrone; Claudia Camerino; Bodvael Fraysse; Massimo Mirabella; Serenella Servidei; Urs T Rüegg; Diana Conte Camerino
Journal:  J Pharmacol Exp Ther       Date:  2003-01       Impact factor: 4.030

8.  Tumor necrosis factor-alpha decreases insulin-like growth factor-I messenger ribonucleic acid expression in C2C12 myoblasts via a Jun N-terminal kinase pathway.

Authors:  Robert A Frost; Gerald J Nystrom; Charles H Lang
Journal:  Endocrinology       Date:  2003-05       Impact factor: 4.736

Review 9.  Muscular dystrophies: influence of physical conditioning on the disease evolution.

Authors:  Tor Ansved
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2003-07       Impact factor: 4.294

Review 10.  The role of corticosteroids in muscular dystrophy: a critical appraisal.

Authors:  Corrado Angelini
Journal:  Muscle Nerve       Date:  2007-10       Impact factor: 3.217

View more
  4 in total

1.  Adaptive strength gains in dystrophic muscle exposed to repeated bouts of eccentric contraction.

Authors:  Jarrod A Call; Michael D Eckhoff; Kristen A Baltgalvis; Gordon L Warren; Dawn A Lowe
Journal:  J Appl Physiol (1985)       Date:  2011-09-29

2.  Voluntary wheel running in dystrophin-deficient (mdx) mice: Relationships between exercise parameters and exacerbation of the dystrophic phenotype.

Authors:  Gayle M Smythe; Jason D White
Journal:  PLoS Curr       Date:  2011-12-18

3.  Tracking disease progression non-invasively in Duchenne and Becker muscular dystrophies.

Authors:  Pietro Spitali; Kristina Hettne; Roula Tsonaka; Mohammed Charrout; Janneke van den Bergen; Zaïda Koeks; Hermien E Kan; Melissa T Hooijmans; Andreas Roos; Volker Straub; Francesco Muntoni; Cristina Al-Khalili-Szigyarto; Marleen J A Koel-Simmelink; Charlotte E Teunissen; Hanns Lochmüller; Erik H Niks; Annemieke Aartsma-Rus
Journal:  J Cachexia Sarcopenia Muscle       Date:  2018-04-16       Impact factor: 12.910

4.  Molecular, physiological, and motor performance defects in DMSXL mice carrying >1,000 CTG repeats from the human DM1 locus.

Authors:  Aline Huguet; Fadia Medja; Annie Nicole; Alban Vignaud; Céline Guiraud-Dogan; Arnaud Ferry; Valérie Decostre; Jean-Yves Hogrel; Friedrich Metzger; Andreas Hoeflich; Martin Baraibar; Mário Gomes-Pereira; Jack Puymirat; Guillaume Bassez; Denis Furling; Arnold Munnich; Geneviève Gourdon
Journal:  PLoS Genet       Date:  2012-11-29       Impact factor: 5.917

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.